{
    "2018-01-17": [
        [
            {
                "time": "2018-01-02",
                "original_text": "U.S. court invalidates patent on J&J cancer drug Zytiga",
                "features": {
                    "keywords": [
                        "court",
                        "invalidates",
                        "patent",
                        "J&J",
                        "cancer",
                        "drug",
                        "Zytiga"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "&quot;Fast Money&quot; final trades: JNJ, INTC and more",
                "features": {
                    "keywords": [
                        "Fast Money",
                        "trades",
                        "JNJ",
                        "INTC"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Johnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "ZYTIGA",
                        "Inter Partes Reviews"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "7 More Dividend Stocks Benefiting From the Tax Cut",
                "features": {
                    "keywords": [
                        "Dividend Stocks",
                        "Tax Cut"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "No More Tears: Johnson & Johnson Is Still in an Uptrend and Keeping Me Humble",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Uptrend"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Ortho-Clinical Diagnostics SA -- Moody's affirms Ortho-Clinical's ratings, outlook revised to stable",
                "features": {
                    "keywords": [
                        "Ortho-Clinical Diagnostics",
                        "Moody's",
                        "ratings",
                        "stable"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "SPLG, JPM, JNJ, ORCL: ETF Inflow Alert",
                "features": {
                    "keywords": [
                        "SPLG",
                        "JPM",
                        "JNJ",
                        "ORCL",
                        "ETF",
                        "Inflow"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Kyprolis Could Boost Amgen’s Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Kyprolis",
                        "Amgen",
                        "Revenue Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "3 Dividend Stocks That Pay Out Over $8 Billion a Year",
                "features": {
                    "keywords": [
                        "Dividend Stocks",
                        "$8 Billion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Zoetis Inc. (ZTS) Ex-Dividend Date Scheduled for January 18, 2018",
                "features": {
                    "keywords": [
                        "Zoetis",
                        "Ex-Dividend",
                        "Date"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Johnson & Johnson Aims to Start 2018 Healthy",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Healthy",
                        "2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Amgen’s Xgeva Could Witness Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Xgeva",
                        "Revenue Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Exclusive: J&J attracts Chinese interest for diabetes business in potential $3-4 billion deal - sources",
                "features": {
                    "keywords": [
                        "J&J",
                        "Chinese interest",
                        "diabetes",
                        "business",
                        "$3-4 billion",
                        "deal"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}